Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment.

Zietsch J, Ziegenhagen N, Heppner FL, Reuss D, von Deimling A, Holtkamp N.

PLoS One. 2010 Jul 29;5(7):e11858. doi: 10.1371/journal.pone.0011858.

2.

Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.

Holtkamp N, Okuducu AF, Mucha J, Afanasieva A, Hartmann C, Atallah I, Estevez-Schwarz L, Mawrin C, Friedrich RE, Mautner VF, von Deimling A.

Carcinogenesis. 2006 Mar;27(3):664-71. Epub 2005 Dec 15.

PMID:
16357008
3.

PDGFRA, PDGFRB, EGFR, and downstream signaling activation in malignant peripheral nerve sheath tumor.

Perrone F, Da Riva L, Orsenigo M, Losa M, Jocollè G, Millefanti C, Pastore E, Gronchi A, Pierotti MA, Pilotti S.

Neuro Oncol. 2009 Dec;11(6):725-36. doi: 10.1215/15228517-2009-003.

4.
5.

Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.

Lyros O, Mueller A, Heidel F, Schimanski CC, Gockel I, Galle PR, Lang H, Moehler M.

Int J Cancer. 2010 Sep 1;127(5):1197-208. doi: 10.1002/ijc.25137.

6.

The three receptor tyrosine kinases c-KIT, VEGFR2 and PDGFRα, closely spaced at 4q12, show increased protein expression in triple-negative breast cancer.

Jansson S, Bendahl PO, Grabau DA, Falck AK, Fernö M, Aaltonen K, Rydén L.

PLoS One. 2014 Jul 15;9(7):e102176. doi: 10.1371/journal.pone.0102176. eCollection 2014.

7.

Imatinib mesylate inhibits cell invasion of malignant peripheral nerve sheath tumor induced by platelet-derived growth factor-BB.

Aoki M, Nabeshima K, Koga K, Hamasaki M, Suzumiya J, Tamura K, Iwasaki H.

Lab Invest. 2007 Aug;87(8):767-79. Epub 2007 Jun 11.

8.

Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.

Reuss DE, Mucha J, Hagenlocher C, Ehemann V, Kluwe L, Mautner V, von Deimling A.

PLoS One. 2013;8(2):e57152. doi: 10.1371/journal.pone.0057152. Epub 2013 Feb 21.

9.

Distinct phenotypic differences associated with differential amplification of receptor tyrosine kinase genes at 4q12 in glioblastoma.

Burford A, Little SE, Jury A, Popov S, Laxton R, Doey L, Al-Sarraj S, Jürgensmeier JM, Jones C.

PLoS One. 2013 Aug 21;8(8):e71777. doi: 10.1371/journal.pone.0071777. eCollection 2013.

10.

Differentially expressed genes in neurofibromatosis 1-associated neurofibromas and malignant peripheral nerve sheath tumors.

Holtkamp N, Mautner VF, Friedrich RE, Harder A, Hartmann C, Theallier-Janko A, Hoffmann KT, von Deimling A.

Acta Neuropathol. 2004 Feb;107(2):159-68. Epub 2003 Dec 13.

PMID:
14673600
11.

Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway.

Ping SY, Wu CL, Yu DS.

Urol Oncol. 2012 Sep;30(5):652-9. doi: 10.1016/j.urolonc.2010.07.001. Epub 2010 Sep 29.

PMID:
20884251
12.

Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N.

Mol Cancer Ther. 2008 May;7(5):1237-45. doi: 10.1158/1535-7163.MCT-07-2335.

13.

Ligand-dependent platelet-derived growth factor receptor (PDGFR)-alpha activation sensitizes rare lung cancer and sarcoma cells to PDGFR kinase inhibitors.

McDermott U, Ames RY, Iafrate AJ, Maheswaran S, Stubbs H, Greninger P, McCutcheon K, Milano R, Tam A, Lee DY, Lucien L, Brannigan BW, Ulkus LE, Ma XJ, Erlander MG, Haber DA, Sharma SV, Settleman J.

Cancer Res. 2009 May 1;69(9):3937-46. doi: 10.1158/0008-5472.CAN-08-4327. Epub 2009 Apr 14.

14.

Inhibition of activated receptor tyrosine kinases by Sunitinib induces growth arrest and sensitizes melanoma cells to Bortezomib by blocking Akt pathway.

Yeramian A, Sorolla A, Velasco A, Santacana M, Dolcet X, Valls J, Abal L, Moreno S, Egido R, Casanova JM, Puig S, Vilella R, Llombart-Cussac A, Matias-Guiu X, Martí RM.

Int J Cancer. 2012 Feb 15;130(4):967-78. doi: 10.1002/ijc.26096. Epub 2011 Jun 18.

15.

Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner.

Byer SJ, Eckert JM, Brossier NM, Clodfelder-Miller BJ, Turk AN, Carroll AJ, Kappes JC, Zinn KR, Prasain JK, Carroll SL.

Neuro Oncol. 2011 Jan;13(1):28-41. doi: 10.1093/neuonc/noq146. Epub 2010 Nov 12.

17.

Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.

Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.

Pediatr Blood Cancer. 2009 Jul;52(7):767-71. doi: 10.1002/pbc.21909.

PMID:
19326424
18.

Characterization of the amplicon on chromosomal segment 4q12 in glioblastoma multiforme.

Holtkamp N, Ziegenhagen N, Malzer E, Hartmann C, Giese A, von Deimling A.

Neuro Oncol. 2007 Jul;9(3):291-7. Epub 2007 May 15.

19.

EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.

Holtkamp N, Malzer E, Zietsch J, Okuducu AF, Mucha J, Mawrin C, Mautner VF, Schildhaus HU, von Deimling A.

Neuro Oncol. 2008 Dec;10(6):946-57. doi: 10.1215/15228517-2008-053. Epub 2008 Jul 23.

20.

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.

J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27.

Supplemental Content

Support Center